Citations

Mayo Clinic

Showing 10 of 108522 citations.

Quality Indicators Common to All Gastrointestinal Endoscopic Procedures
Elmunzer, B. Joseph , Anderson, Michelle A. , Mishra, Girish, Rex, Douglas K. , Shaheen, Nicholas J. , Yadlapati, Rena

American Journal of Gastroenterology | August 22, 2024 | Volume: 119 | Issue: 9 | Pages: 1781-1791

10.14309/ajg.0000000000002988 | PMID 39167096 Get It

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD + acute myeloid leukemia
Hamilton, Betty K. , Pandya, Bhavik J. , Ivanescu, Cristina, Elsouda, Dina, Hamadani, Mehdi , Chen, Yi‐Bin , Levis, Mark J. , Ueda, Masumi , Litzow, Mark R. , Soiffer, Robert J. , Üstün, Celalettin , Perl, Alexander E. , Singh, Anurag K. , Geller, Nancy L. , Hasabou, Nahla, Rosales, Matt, Cella, David , Corredoira, Laura, Pestana, Carolina , Horowitz, Mary M. , Logan, Brent R., Ueda Oshima, Masumi , Geller, Nancy , Hamadani, Mehdi

Blood Advances | August 22, 2024 | Volume: 8 | Issue: 19 | Pages: 5091-5099

10.1182/bloodadvances.2024013746 | PMID 39167766 Get It

Abstract The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia (AML). The primary analysis demonstrated no statistically significant difference in relapse-free survival (RFS); however, patients with FLT3-ITD measurable residual disease (MRD) peri-HCT had significantly longer RFS with gilteritinib. This analysis investigates the effect of post-HCT gilteritinib vs placebo on health-related quality of life (HRQOL). HRQOL was measured with Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), FACT-Leukemia (FACT-Leu), and EuroQOL-5 Dimensions (EQ-5D-5L) at post-HCT randomization; day 29; months 3, 6, 12, 18, 24; and/or end of therapy. HRQOL and clinically meaningful differences were summarized using descriptive statistics and compared using mixed model repeated measures to evaluate longitudinal change from baseline and stratified Cox model to evaluate time to improvement. HRQOL completion rate was acceptable (>70%) across all time points and measures. There were no differences in HRQOL scores at any time point between cohorts. Clinically meaningful and time to improvement in HRQOL were similar in both arms. Despite higher treatment-emergent adverse effects with gilteritinib, response to the question of being “bothered by side effects of treatment” did not differ between groups. Subgroup analysis of MRD-positive and negative patients demonstrated no differences in HRQOL between arms. For patients with FLT3-ITD+ AML undergoing HCT, gilteritinib maintenance was not associated with any difference in HRQOL or patient-reported impact of side effects. This trial was registered at www.ClinicalTrials.gov as #NCT02997202.
Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction
Jain, C. Charles , Melenovský, Vojtěch , Asokan, Aneesh K , Carter, Rickey E. , Jensen, Michael D. , Borlaug, Barry A. , Reddy, Yogesh N.V. , Charles Jain, C , Nair, Sreekumaran, Borlaug, Barry A , Nishimura, Rick , Carter, Rickey E , Melenovský, Vojtěch , Haluzı́k, Martin , Nair, K. Sreekumaran

European Heart Journal | August 22, 2024 | Volume: 45 | Issue: 37 | Pages: 3889-3891

10.1093/eurheartj/ehae534 | PMID 39167062 Get It

Alcohol Use Disorder Following Bariatric Surgery Leading to Cirrhosis and Hepatorenal Syndrome
Davison, Jenna , Howick, James F. , Shah, Neel , Davison, Jenna M , Howick V, James F

Annals of Internal Medicine: Clinical Cases | August 22, 2024 | Volume: 3 | Issue: 8 | Pages: No page available

10.7326/aimcc.2024.0290 Get It

Calcinosis Cutis
Howick, James F. , Bhuiyan, Mohammed Nadir , Bhuiyan, M Nadir , Howick V, James F

Annals of Internal Medicine: Clinical Cases | August 22, 2024 | Volume: 3 | Issue: 8 | Pages: No page available

10.7326/aimcc.2024.0272 Get It

Thymoma in an Older Woman Presenting as Bowel Obstruction
Farooqui, Naba , Matulis, John C.

Annals of Internal Medicine: Clinical Cases | August 22, 2024 | Volume: 3 | Issue: 8 | Pages: No page available

10.7326/aimcc.2023.1463 Get It

Effusive Constrictive Pericarditis in the Era of COVID-19
Sharma, Shriya , Luce, Caitlyn, Desai, Aarti , Goswami, Rohan , Goswami, Rohan M , Desai, Aarti , Pham, Si M. , Martin, Archer Kilbourne , Ruiz, Jose

Annals of Internal Medicine: Clinical Cases | August 22, 2024 | Volume: 3 | Issue: 8 | Pages: No page available

10.7326/aimcc.2023.1360 Get It

Anatomical evaluation of the superficial parasternal intercostal plane block
Harbell, Monica W. , Nelson, James A. , Seamans, David P. , Craner, Ryan C., Harbell, Monica W , Craner, Ryan, Nelson, James A, Langley, Natalie R.

Regional Anesthesia & Pain Medicine | August 22, 2024 | Volume: 50 | Issue: 12 | Pages: 948-952

10.1136/rapm-2024-105818 | PMID 39174050 Get It

Background and objectives Few cadaveric studies have evaluated the dye spread with superficial parasternal intercostal plane (SPIP) blocks. In this study, we examined the dye spread of an ultrasound-guided SPIP block in a human cadaveric model with single and double injection techniques. Methods Seven single and four double ultrasound-guided SPIP blocks were performed in seven unembalmed human cadavers using an in-plane approach with the transducer oriented parasagitally 1 cm lateral to the sternum. For the single SPIP, 20 mL of 0.166% methylene blue was injected in the second or third intercostal space into the plane between the Pec major muscle and internal intercostal muscles. For the double SPIP, 10 mL of 0.166% methylene blue was injected in the SPIP at one intercostal space with an additional 10 mL injected in the SPIP two intercostal spaces caudally. The extent of dye spread was documented. Results For all SPIP injections, there was consistent mediolateral spread from the sternum to the mid-clavicular line, with many extending laterally to the anterior axillary line. There was craniocaudal spread to a median of 2 intercostal muscles with a single SPIP and 3 intercostal muscles with a double SPIP. There was a median spread to 1 intercostal nerve for the single SPIP and 1.5 intercostal nerves with the double SPIP. Conclusions The SPIP block demonstrated limited spread in this cadaver study. A single injection of this block may be of limited value and multiple SPIP injections may be needed to have adequate spread for anterior thoracic procedures.
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
Monaghan, Sara A. , Eck, Steven , Bunting, Silvia T., Dong, Xiangyang X., Durso, Robert J., Gonneau, Christèle , Hays, Amanda , Illingworth, Andrea , League, Stacy C., Linskens, Eleni , McCausland, Megan, McCloskey, Thomas W., Rolf, Nina , Wallace, Paul K. , Litwin, Virginia , Kern, Wolfgang , Deeb, George , Nash, Veronica, Olteanu, Horatiu , Wallace, Paul K , Olteanu, Horatiu , Kern, Wolfgang , Shi, Min

Cytometry Part B: Clinical Cytometry | August 22, 2024 | Volume: 108 | Issue: 3 | Pages: 252-266

10.1002/cyto.b.22202 | PMID 39165120 Get It

AbstractThe Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).